🔴 ELTX is trading 5.2% down today on dilution concerns following a $15M offering

ELTX is trading 5.2% down at $3.12 as investors weigh the impact of a recent capital raise against clinical trial progress.

• The stock is pulling back following a $15 million registered direct offering scheduled to close around July 6, leading to investor concerns over share dilution.
• The decline follows a period of high volatility and a sharp rebound driven by news regarding Phase 2/Phase 3 plans for ELI‑002 7P.
• Traders are currently digesting the balance between the company's strengthened financing and the immediate impact of the new share issuance.